Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings


The risk of tuberculosis (TB) is variable among individuals with latent Mycobacterium tuberculosis infection (LTBI), but validated estimates of personalized risk are lacking. In pooled data from 18 systematically identified cohort studies from 20 countries, including 80,468 individuals tested for LTBI, 5-year cumulative incident TB risk among people with untreated LTBI was 15.6% (95% confidence interval (CI), 8.0–29.2%) among child contacts, 4.8% (95% CI, 3.0–7.7%) among adult contacts, 5.0% (95% CI, 1.6–14.5%) among migrants and 4.8% (95% CI, 1.5–14.3%) among immunocompromised groups. We confirmed highly variable estimates within risk groups, necessitating an individualized approach to risk stratification. Therefore, we developed a personalized risk predictor for incident TB (PERISKOPE-TB) that combines a quantitative measure of T cell sensitization and clinical covariates. Internal–external cross-validation of the model demonstrated a random effects meta-analysis C-statistic of 0.88 (95% CI, 0.82–0.93) for incident TB. In decision curve analysis, the model demonstrated clinical utility for targeting preventative treatment, compared to treating all, or no, people with LTBI. We challenge the current crude approach to TB risk estimation among people with LTBI in favor of our evidence-based and patient-centered method, in settings aiming for pre-elimination worldwide.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Population-level cumulative risk of incident TB during follow-up.
Fig. 2: Visual representations of associations between predictors and incident TB.
Fig. 3: Forest plots showing model discrimination and calibration metrics for predicting 2-year risk of incident TB.
Fig. 4: Distribution of predictions and risk of incident TB in four quartiles of risk for people with positive latent TB tests.
Fig. 5: Decision curve analysis.

Similar content being viewed by others

Data availability

The individual participant data pooled for this analysis are subject to data sharing agreements with the original study authors. The data might be shared with interested parties by the corresponding authors of the original studies, subject to data sharing agreements.

Code availability

The final prognostic model developed in this study has been made freely available to enable immediate implementation in clinical practice and independent external validation in new data sets ( The code underlying the prediction tool is available at


  1. World Health Organization. Global Tuberculosis Report 2019 (2019).

  2. World Health Organization. The End TB Strategy (2015).

  3. Getahun, H. et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur. Respir. J. 46, 1563–1576 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Getahun, H., Matteelli, A., Chaisson, R. E. & Raviglione, M. Latent Mycobacterium tuberculosis infection. N. Engl. J. Med. 372, 2127–2135 (2015).

    CAS  PubMed  Google Scholar 

  5. Mack, U. et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur. Respir. J. 33, 956–973 (2009).

    CAS  PubMed  Google Scholar 

  6. Sterling, T. R. et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm. Rep. 69, 1–11 (2020).

    PubMed  PubMed Central  Google Scholar 

  7. Pai, M. et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin. Microbiol. Rev. 27, 3–20 (2014).

    PubMed  PubMed Central  Google Scholar 

  8. Rangaka, M. X. et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 12, 45–55 (2012).

    CAS  PubMed  Google Scholar 

  9. Abubakar, I. et al. Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. Lancet Infect. Dis. 18, 1077–1087 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Gao, J. et al. Knowledge and perceptions of latent tuberculosis infection among Chinese immigrants in a Canadian urban centre. Int. J. Fam. Med. 2015, 546042 (2015).

    Google Scholar 

  11. Alsdurf, H., Hill, P. C., Matteelli, A., Getahun, H. & Menzies, D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect. Dis. 16, 1269–1278 (2016).

    PubMed  Google Scholar 

  12. Campbell, J. R., Winters, N. & Menzies, D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-γ release assay result: systematic review and meta-analysis. BMJ 368, m549 (2020).

    PubMed  PubMed Central  Google Scholar 

  13. Behr, M. A., Edelstein, P. H. & Ramakrishnan, L. Revisiting the timetable of tuberculosis. BMJ 362, k2738 (2018).

    PubMed  PubMed Central  Google Scholar 

  14. Winje, B. A. et al. Stratification by interferon-γ release assay level predicts risk of incident TB. Thorax 73, 652–661 (2018).

    Google Scholar 

  15. Andrews, J. R. et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respir. Med. 5, 282–290 (2017).

    PubMed  PubMed Central  Google Scholar 

  16. Gupta, R. K. et al. Quantitative IFN-γ release assay and tuberculin skin test results to predict incident tuberculosis: a prospective cohort study. Am. J. Respir. Crit. Care Med. 201, 984-991 (2020).

  17. Altet, N. et al. Predicting the development of tuberculosis with the tuberculin skin test and QuantiFERON testing. Ann. Am. Thorac. Soc. 12, 680–688 (2015).

    PubMed  Google Scholar 

  18. Diel, R., Loddenkemper, R., Niemann, S., Meywald-Walter, K. & Nienhaus, A. Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. Am. J. Respir. Crit. Care Med. 183, 88–95 (2011).

    CAS  PubMed  Google Scholar 

  19. Dobler, C. C. & Marks, G. B. Risk of tuberculosis among contacts in a low-incidence setting. Eur. Respir. J. 41, 1459–1461 (2013).

    PubMed  Google Scholar 

  20. Geis, S. et al. How can we achieve better prevention of progression to tuberculosis among contacts? Eur. Respir. J. 42, 1743–1746 (2013).

    PubMed  Google Scholar 

  21. Haldar, P. et al. Single-step QuantiFERON screening of adult contacts: a prospective cohort study of tuberculosis risk. Thorax 68, 240–246 (2013).

    PubMed  Google Scholar 

  22. Sloot, R., Van Der Loeff, M. F. S., Kouw, P. M. & Borgdorff, M. W. Risk of tuberculosis after recent exposure: a 10-year follow-up study of contacts in Amsterdam. Am. J. Respir. Crit. Care Med. 190, 1044–1052 (2014).

    PubMed  Google Scholar 

  23. Yoshiyama, T., Harada, N., Higuchi, K., Saitou, M. & Kato, S. Use of the QuantiFERON-TB Gold in Tube test for screening TB contacts and predictive value for active TB. Infect. Dis. 47, 542–549 (2015).

    Google Scholar 

  24. Zellweger, J.-P. et al. Risk assessment of tuberculosis in contacts by IFN-γ release assays. A Tuberculosis Network European Trials Group study. Am. J. Respir. Crit. Care Med. 191, 1176–1184 (2015).

    CAS  PubMed  Google Scholar 

  25. Gupta, R. K. et al. Evaluation of QuantiFERON-TB Gold Plus for predicting incident tuberculosis among recent contacts: a prospective cohort study. Ann. Am. Thorac. Soc. 17, 646–650 (2020).

  26. Aichelburg, M. C. et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-γ release assay in HIV-1-infected individuals. Clin. Infect. Dis. 48, 954–962 (2009).

    CAS  PubMed  Google Scholar 

  27. Doyle, J. S. et al. Latent tuberculosis screening using interferon-γ release assays in an Australian HIV-infected cohort: is routine testing worthwhile? J. Acquir. Immune Defic. Syndr. 66, 48–54 (2014).

    CAS  PubMed  Google Scholar 

  28. Lange, B., Vavra, M., Kern, W. V. & Wagner, D. Development of tuberculosis in immunocompromised patients with a positive tuberculosis-specific IGRA. Int. J. Tuberc. Lung Dis. 16, 492–495 (2012).

    CAS  PubMed  Google Scholar 

  29. Sester, M. et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am. J. Respir. Crit. Care Med. 190, 1168–1176 (2014).

    PubMed  Google Scholar 

  30. Munoz, L. et al. Immunodiagnostic tests’ predictive values for progression to tuberculosis in transplant recipients: a prospective cohort study. Transplant. Direct 1, e12 (2015).

    PubMed  PubMed Central  Google Scholar 

  31. Roth, D. Z. et al. Impact of interferon-γ release assay on the latent tuberculosis cascade of care: a population-based study. Eur. Respir. J. 49, 1601546 (2017).

    PubMed  Google Scholar 

  32. Erkens, C. G. M. et al. Risk of developing tuberculosis disease among persons diagnosed with latent tuberculosis infection in the Netherlands. Eur. Respir. J. 48, 1420–1428 (2016).

    PubMed  Google Scholar 

  33. Zenner, D., Loutet, M. G., Harris, R., Wilson, S. & Ormerod, L. P. Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation. Eur. Respir. J. 50, 1602505 (2017).

    PubMed  PubMed Central  Google Scholar 

  34. Debray, T. P. A. et al. Individual participant data (IPD) meta-analyses of diagnostic and prognostic modeling studies: guidance on their use. PLoS Med. 12, e1001886 (2015).

    PubMed  PubMed Central  Google Scholar 

  35. Vickers, A. J., van Calster, B. & Steyerberg, E. W. A simple, step-by-step guide to interpreting decision curve analysis. Diagn. Progn. Res. 3, 18 (2019).

    PubMed  PubMed Central  Google Scholar 

  36. Zhang, Z. et al. Decision curve analysis: a technical note. Ann. Transl. Med. 6, 19 (2018).

    Google Scholar 

  37. Steyerberg, E. W. & Harrell, F. E. Prediction models need appropriate internal, internal–external, and external validation. J. Clin. Epidemiol. 69, 245–247 (2016).

    PubMed  Google Scholar 

  38. Martinez, L. et al. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet 395, 973–984 (2020).

    PubMed  Google Scholar 

  39. Saunders, M. J. et al. A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study. Lancet Infect. Dis. 17, 1190–1199 (2017).

    PubMed  Google Scholar 

  40. Saunders, M. J. et al. A household-level score to predict the risk of tuberculosis among contacts of patients with tuberculosis: a derivation and external validation prospective cohort study. Lancet Infect. Dis. 20, 110–122 (2020).

    PubMed  PubMed Central  Google Scholar 

  41. Li, R. et al. Two clinical prediction tools to improve tuberculosis contact investigation. Clin. Infect. Dis. (2020).

  42. Menzies, D., Gardiner, G., Farhat, M., Greenaway, C. & Pai, M. Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int. J. Tuberc. Lung Dis. 12, 498–505 (2008).

    CAS  PubMed  Google Scholar 

  43. Stewart, L. A. et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data. JAMA 313, 1657 (2015).

    Google Scholar 

  44. Collins, G. S., Reitsma, J. B., Altman, D. G. & Moons, K. G. M. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 350, g7594 (2015).

    PubMed  Google Scholar 

  45. Audigier, V. et al. Multiple imputation for multilevel data with continuous and binary variables. Stat. Sci. 33, 160–183 (2018).

    Google Scholar 

  46. Nemes, E. et al. Prevention of M. Tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N. Engl. J. Med. 379, 138–149 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Katelaris, A. L. et al. Effectiveness of BCG vaccination against Mycobacterium tuberculosis infection in adults: a cross-sectional analysis of a UK-based cohort. J. Infect. Dis. 221, 146–155 (2020).

    CAS  PubMed  Google Scholar 

  48. White, I. R., Royston, P. & Wood, A. M. Multiple imputation using chained equations: issues and guidance for practice. Stat. Med. 30, 377–399 (2011).

    PubMed  Google Scholar 

  49. Drain, P. K. et al. Incipient and subclinical tuberculosis: clinical review of early stages and progression of infection. Clin. Microbiol. Rev. 31, e00021-18 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Gupta, R. K. et al. Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. Lancet. Respir. Med. 8, 395–406 (2020).

  51. Roe, J. et al. Blood transcriptomic stratification of short-term risk in contacts of tuberculosis. Clin. Infect. Dis. 70, 731–737 (2019).

  52. World Health Organization. Latent TB Infection: updated and consolidated guidelines for programmatic management (2018).

  53. Groenwold, R. H. H. et al. Explicit inclusion of treatment in prognostic modeling was recommended in observational and randomized settings. J. Clin. Epidemiol. 78, 90–100 (2016).

    PubMed  Google Scholar 

  54. Wells, G. et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses

  55. Zenner, D. et al. Treatment of latent tuberculosis infection. Ann. Intern. Med. 167, 248 (2017).

    PubMed  Google Scholar 

  56. Balduzzi, S., Rücker, G. & Schwarzer, G. How to perform a meta-analysis with R: a practical tutorial. Evid. Based Ment. Health 22, 153–160 (2019).

    PubMed  Google Scholar 

  57. Seddon, J. A. et al. The impact of BCG vaccination on tuberculin skin test responses in children is age dependent: evidence to be considered when screening children for tuberculosis infection. Thorax 71, 932–939 (2016).

    PubMed  PubMed Central  Google Scholar 

  58. Cobelens, F. G. et al. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin. Infect. Dis. 43, 634–639 (2006).

    PubMed  Google Scholar 

  59. Harrell, F. E. Biostatistical Modeling (2004).

  60. Audigier, V. & Resche-Rigon, M. micemd: multiple imputation by chained equations with multilevel data. R package, version 1.6.0 (2019).

  61. Rubin, D. B. Multiple Imputation for Nonresponse In Surveys (Wiley-Interscience, 2004).

  62. Royston, P. & Parmar, M. K. B. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat. Med. 21, 2175–2197 (2002).

    PubMed  Google Scholar 

  63. Clements, M. & Liu, X.-R. rstpm2: smooth survival models, including generalized survival models. R package, version 1.5.1 (2019).

  64. Bower, H. et al. Capturing simple and complex time-dependent effects using flexible parametric survival models: a simulation study. Commun. Stat. Simul. Comput. (2019).

  65. Steyerberg, E. W. & Vergouwe, Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur. Heart J. 35, 1925–1931 (2014).

    PubMed  PubMed Central  Google Scholar 

  66. Westeneng, H.-J. et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 17, 423–433 (2018).

    PubMed  Google Scholar 

  67. Snell, K. I., Ensor, J., Debray, T. P., Moons, K. G. & Riley, R. D. Meta-analysis of prediction model performance across multiple studies: which scale helps ensure between-study normality for the C-statistic and calibration measures? Stat. Methods Med. Res. 27, 3505–3522 (2018).

    PubMed  Google Scholar 

  68. Sjoberg, D. D. dca: decision curve analysis. R package, version (2020).

Download references


This study was funded by the National Institute for Health Research (NIHR) (DRF-2018–11-ST2-004 to R.K.G. and SRF-2011-04-001 and NF-SI-0616-10037 to I.A.), the Wellcome Trust (207511/Z/17/Z to M.N.) and NIHR biomedical research funding to University College London Hospitals. C.L. is funded by the German Center for Infection Research. J.S.D. receives salary support from the National Health and Medical Research Council (Australia). This paper presents independent research supported by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health and Social Care. The study funders had no role in the conceptualization, design, data collection, analysis, decision to publish or preparation of the manuscript. The authors would like to thank all of the research teams involved in the primary studies that contributed data for this analysis.

Author information

Authors and Affiliations



R.K.G. and I.A. conceived of the study and led the pooling of data. R.K.G., M.X.R., A.C, M.L., M.N. and I.A. wrote the study protocol and developed the analysis plan. R.K.G. conducted the analyses and wrote the first draft of the manuscript. R.K.G., C.J.C. and M.K. performed the systematic literature review. M.Q. and A.C. provided statistical and multiple imputation expertise. A.Y. and R.K.G. developed the website interface for the risk predictor tool. M.C.A., N.A., R.D., C.C.D., J.D., J.S.D., C.E., S.G., P.H., A.M.H., T.H., J.C.J., C.L., B.L., F.v.L., L.M., C.R., K.R., D.R., M.S., R.S., G.S., G.W., T.Y., J.-P.Z. and D.Z. contributed primary data and assisted with interpretation. R.W.A contributed to data interpretation. All authors critically reviewed and approved the manuscript before submission.

Corresponding author

Correspondence to Ibrahim Abubakar.

Ethics declarations

Competing interests

J.S.D.ʼs institution receives investigator-initiated research grants and consultancy income from Gilead Sciences, AbbVie, Bristol Myers Squibb and Merck. The Burnet Institute receives funding from the Victorian Government Operational Infrastructure Fund. C.L. reports honoraria from Chiesi, Gilead, Insmed, Janssen, Lucane, Novartis, Oxoid, Berlin Chemie (for participation at sponsored symposia) and Oxford Immunotec (to attend a scientific advisory board meeting), all outside of the submitted work. M.S. reports receipt of test kits free of charge from Qiagen and from Oxford Immunotec for investigator-initiated research projects. I.A. reports receiving test kits free of charge from Qiagen for an investigator-initiated research project25. C.E. reports receiving test kits free of charge from Qiagen for investigator-initiated research projects outside of the submitted work. The authors declare no other conflicts of interest.

Additional information

Peer review information Alison Farrell is the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 Flow chart outlining systematic review process.

The systematic search strategy and eligibility criteria are shown in Supplementary Tables 8 and 9.

Extended Data Fig. 2 Flow chart showing inclusion of participants in the population-level and prediction modelling analyses.

The systematic search strategy and eligibility criteria are shown in Supplementary Tables 8 and 9.

Extended Data Fig. 3 Cumulative risk of prevalent and incident tuberculosis during follow-up.

Risk is stratified by binary latent TB test result, provision of preventative treatment, and indication for screening among participants with untreated latent infection (total n = 80,468 participants). Cumulative risk is estimated using flexible parametric survival models with random effects for the intercept by source study, separately fitted to each risk group. Prevalent TB cases (diagnosed within 42 days of recruitment) are included in this sensitivity analysis. Each plot is presented as point estimates (solid line) and 95% confidence intervals (shaded area). PT = preventative treatment.

Extended Data Fig. 4 Pooled TB incidence rates among adults, stratified by risk group.

Pooled incidence rates are shown on log10 scale among participants with: latent TB infection (LTBI) with no preventative therapy (PT); LTBI commencing PT; and without evidence of LTBI. Rates are further stratified by follow-up interval (0–2 years vs. 2–5 years) and indication for screening (total n = 52,576 participants). Pooled incidence rate estimates were derived from random intercept Poisson regression models, without continuity correction for studies with zero events. Numeric results are shown for the subgroups with untreated latent TB infection in the forest plots in Extended Data Fig. 5. Plots show point estimates (filled circles) and 95% confidence intervals (vertical error bars). No pooled estimate could be calculated for child contacts without evidence of LTBI for the 2–5 year interval since there were no incident events.

Extended Data Fig. 5 Forest plots showing incidence rates by source study among participants with untreated LTBI.

Forest plots are stratified by follow-up interval (0–2 years vs. 2–5 years) and indication for screening (total n = 52,576 participants). Pooled incidence rate estimates (shown as diamonds) were derived from random intercept Poisson regression models, without continuity correction for studies with zero events. Incidence rates per study are shown with a continuity correction of 0.5 for studies with zero events. Plots show study-level point estimates (grey squares) and 95% confidence intervals (CIs; horizontal error bars).

Extended Data Fig. 6 Calibration plots from internal-external validation of prediction model, stratified by validation study.

Data from nine primary validation studies are shown, from internal-external cross-validation of the model (developed among n = 31,090 participants; validated among 25,504 in this analysis). X-axis shows predicted risk, in quintiles, with corresponding Kaplan Meier 2-year risk of incident TB on the Y-axis (95% confidence intervals are shown by vertical error bars).

Extended Data Fig. 7 Model validation sensitivity analyses.

Forest plots showing recalculation of the C-statistics from internal-external cross validation, limiting validation sets to a, participants who did not receive preventative therapy (n = 23,060 participants); b, participants with a positive LTBI test (n = 9,063 participants); and c, binary LTBI test results (using an average quantitative positive or negative LTBI test result as appropriate, based on the medians among the study population; n = 25,504 participants). ‘TB’ column indicates number of incident TB cases within 2 years of study entry and ‘N’ indicates total participants per study included in analysis. Each forest plot shows point estimates (squares) and 95% confidence intervals (error bars). Pooled estimates are shown as diamonds. Panel d, shows decision curve analyses (n = 6,418 participants) when using the prediction model using a binary LTBI test result, compared to the full prediction model, ‘treat all’ and ‘treat none’ strategies across a range of threshold probabilities (x-axis). Net benefit appeared higher for the binary model than either the strategies of treating all patients with evidence of LTBI, or no patients, throughout the range of threshold probabilities. The full model had highest net benefit across most threshold probabilities.

Extended Data Fig. 8 Data supporting assumptions underlying PERISKOPE-TB model.

a, Quantitative results for the tuberculin skin test (TST), QuantiFERON Gold-in-tube (QFT-GIT) and T-SPOT.TB are normalised to a percentile scale using a head-to-head population among whom all three tests were performed from 3 studies including recent TB contacts, migrants and immunocompromised participants (n = 8,335; 158 TB cases). We examined the association between normalised test result and risk of incident TB using Cox proportional hazards models with restricted cubic splines. Normalised results for each test appeared to be associated with similar risk of incident TB. b, Kaplan Meier plots from pooled dataset showing cumulative risk of incident TB, stratified by proximity and infectiousness of index cases among contacts (n = 22,231 participants). There was no evidence of separation of risk of additional subgroups of the ‘other’ (non-smear positive household) contacts stratum. PTB = pulmonary TB; EPTB = extra-pulmonary TB. c, Kaplan Meier plots from pooled dataset showing cumulative risk of incident TB among people with positive latent TB tests, stratified by TB incidence in country of birth among migrants from high TB burden countries (n = 1,031 participants). P value represents Log-rank test. d, Kaplan Meier plots from pooled dataset showing cumulative risk of incident TB among people with positive latent TB tests, stratified by country of birth among recent contacts (n = 5,917 participants). P value represents Log-rank test.

Supplementary information

Supplementary Information

Supplementary Tables 1–11.

Reporting Summary

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gupta, R.K., Calderwood, C.J., Yavlinsky, A. et al. Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nat Med 26, 1941–1949 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research